| Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats. | |
| | |
MedLine Citation:
|
PMID: 20813166 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The present study has been designed to explore the protective effect of montelukast (leukotriene receptor antagonist) against intrastriatal quinolinic acid (QA; 300 nmol) and malonic acid (MA; 6 μmol) induced Huntington's like symptoms in rats. Quinolinic acid has been reported to induce excitotoxicity by stimulating the N-methyl-D-aspartate receptor, causing calcium overload which in turn leads to the neurodegeneration. On the other hand, MA, being a reversible inhibitor of mitochondrial enzyme complex-II, leads to energy crisis and free radical generation. Recent studies have reported the therapeutic potential of leukotriene receptor antagonists in different neurodegenerative disorders. However, their exact role is yet to be established. The present study accordingly, is an attempt to investigate the effect of montelukast against QA and MA induced behavioral, biochemical and molecular alterations in rat striatum. Oxidative stress, mitochondrial enzyme complex and tumor necrosis factor-alpha (TNF-α) were evaluated on day 21st and 14th post intrastriatal QA and MA treatment, respectively. Findings of the present study demonstrate significant alteration in the locomotor activity and motor coordination as well as oxidative burden (increased lipid peroxidation, nitrite concentration and decreased endogenous antioxidants), mitochondrial enzyme complex (I, II and IV) activities and TNF-α level, in both intrastriatal QA and MA treated animals. Further, montelukast (0.4, 0.8 mg/kg p.o.) treatment for 21 and 14 days respectively, attenuated the behavioral alterations, oxidative stress, mitochondrial dysfunction and TNF-α level in these models of Huntington's disease in a significant manner. In conclusion, the present study emphasizes the neuroprotective potential of montelukast in the therapeutic management of Huntington like symptoms. |
| | |
Authors:
|
H Kalonia; P Kumar; A Kumar; B Nehru |
Related Documents
:
|
17668196 - Changes of metabolite profile in kainic acid induced hippocampal injury in rats measure... 6806676 - Increases in choline levels in rat brain elicited by meclofenoxate. 1517826 - Pii component of the toad electroretinogram. 3277086 - Immunohistochemical identification of quinolinic acid phosphoribosyltransferase in glia... 17008386 - Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. 5925066 - Synthesis of amino acid residues with reactive side chains under simple conditions. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-09-09 |
Journal Detail:
|
Title: Neuroscience Volume: 171 ISSN: 1873-7544 ISO Abbreviation: Neuroscience Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-18 Completed Date: 2011-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7605074 Medline TA: Neuroscience Country: United States |
Other Details:
|
Languages: eng Pagination: 284-99 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 IBRO. Published by Elsevier Ltd. All rights reserved. |
Affiliation:
|
Pharmacology Division, University Institute of Pharmaceutical Sciences, University Grants Commission-Centre of Advanced Study, Panjab University, Chandigarh-160014, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetates
/
pharmacology*,
therapeutic use Analysis of Variance Animals Behavior, Animal / drug effects Body Weight / drug effects Brain / drug effects, metabolism, ultrastructure Brain Chemistry / drug effects* Catalase / metabolism Disease Models, Animal Dose-Response Relationship, Drug Drug Administration Schedule Gene Expression Regulation / drug effects* Lipid Peroxidation / drug effects Male Malonates / toxicity Mitochondria / drug effects*, metabolism Motor Activity / drug effects Neuroprotective Agents / pharmacology*, therapeutic use Neurotoxicity Syndromes / etiology, pathology, prevention & control* Nitrites / metabolism Quinolines / pharmacology*, therapeutic use Quinolinic Acid / toxicity Rats Rats, Wistar Superoxide Dismutase / metabolism Tetrazolium Salts / diagnostic use Thiazoles / diagnostic use Tumor Necrosis Factor-alpha / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Acetates; 0/Malonates; 0/Neuroprotective Agents; 0/Nitrites; 0/Quinolines; 0/Tetrazolium Salts; 0/Thiazoles; 0/Tumor Necrosis Factor-alpha; 141-82-2/malonic acid; 158966-92-8/montelukast; 298-93-1/thiazolyl blue; 89-00-9/Quinolinic Acid; EC 1.11.1.6/Catalase; EC 1.15.1.1/Superoxide Dismutase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Astroglial connexin immunoreactivity is specifically altered at ?-amyloid plaques in ?-amyloid precu...
Next Document: Derangements of post-ischemic cerebral blood flow by protein kinase C delta.